In Florida, Dyadic received the test results from the mice trials in a research program with Sanofi Pasteur indicating that the C1-produced antigen generated an equal, or better, immune response in mice than the industry standard antigen. At the same time, Dyadic joined the EU-funded Zoonoses Anticipation and Preparedness Initiative, a/k/a/ ZAPI, which aims to develop an end-to-end solution for the rapid development, production, regulatory approval and launch of vaccine products to combat epidemic infectious diseases in animals that have the potential to effect the human population.
Led by Merial, Sanofi’s animal health arm, participants within ZAPI include experts from regulatory agencies, academia and industry including AstraZeneca, Utrecht University, University of Bonn, Leiden University and a number of small and medium enterprises (SMEs). We believe that Dyadic’s C1 technology may play a key role in ZAPI as a core enabling technology in a rapid product development and production system.
“We are very encouraged by these results and remain optimistic as to the potential benefits our C1 technology can bring to the biopharmaceutical industry. We believe our C1 Expression System has the potential to aid in the discovery, development and manufacture of new, better and more affordable human and animal vaccines, antibodies, biosimilars and other therapeutic proteins,” said Dyadic’s founder & CEO, Mark Emalfarb.